NSB
Director Trades
| Date | Director | Value |
|---|---|---|
| 26/6/25 | A. Uvarov | $92,750 |
Company News
NeuroScientific Biopharmaceuticals Investigates Use of Stem Cell Technology on Chronic Diseases
NeuroScientific Biopharmaceuticals (ASX: NSB) is investigating the use of its newly-acquired StemSmart stem cell technology for complex indications including refractory Crohn’s disease and steroid-refractory GVHD (graft-versus-host disease). The company recently finalised the acquisition of Isopogen WA, which developed the patented technology for the manufacture of mesenchymal stromal cells (MSC), which are derived from adult human […]
NeuroScientific Biopharmaceuticals acquires Isopogen to advance stem cell therapy for neurodegenerative disorders
NeuroScientific Biopharmaceuticals (ASX: NSB) has announced it will acquire private company Isopogen WA and its StemSmart patented stem cell technology for the manufacture of mesenchymal stromal cells (MSC). The company will incorporate the cellular technology into a special access program involving the use of allogeneic bone marrow-derived MSC to treat neurodegenerative conditions where sustained healing […]
NeuroScientific hails potential breakthrough after early EmtinB study results
NeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-clinical study of its lead compound EmtinB in treating multiple sclerosis (MS). The full report is set to be published by the end of this month, although according to the company’s chief executive officer Matthew Liddelow, the early results already indicate a “potential breakthrough” […]
NeuroScientific’s EmtinB drug achieves positive results in pre-clinical MS research
NeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies using its lead drug candidate EmtinB to treat multiple sclerosis models. Independent research organisation Neuron Experts undertook the study to evaluate EmtimB as a potential therapeutic benefit for MS. MS is one of the most common immune-mediated neurodegenerative conditions with onset ranging between 20 […]
NeuroScientific Biopharmaceuticals posts positive outcomes from glaucoma study on animal models
NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed positive results from a glaucoma study on pig models that indicates the “disease-modifying potential” of its lead drug candidate EmtinB. The drug developer today announced outcomes from a pre-clinical efficacy study in its ophthalmology program, using EmtinB as a therapy for glaucoma – an eye condition that permanently damages […]
NeuroScientific reveals positive results from pre-clinical glaucoma study
Drug developer NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed the first pre-clinical results of an ophthalmology program that has demonstrated the potential for its lead drug candidate EmtinB to become a “revolutionary” treatment for glaucoma. EmtinB is a novel therapeutic peptide developed by NeuroScientific that is most advanced as a treatment for Alzheimer’s disease. In July, […]
NeuroScientific publishes positive results in fight against Alzheimer’s
Alzheimer’s treatment could be set for a significant boost following the publication of what NeuroScientific Biopharmaceuticals (ASX: NSB) calls a “breakthrough study” into its lead drug candidate EmtinB using rat tissue. Contract researcher and neuroscience specialist MD Biosciences carried out the pre-clinical study, with NeuroScientific hoping to move onto human trials later this year. Results […]
NeuroScientific Biopharmaceuticals goes public with its novel EmtinB treatment for Alzheimer’s disease
There is yet more hope for Alzheimer’s sufferers as biopharma solutions continue to make their way onto the ASX for funding and wider recognition. Pharmaceutical company NeuroScientific Biopharmaceuticals (ASX: NSB) has listed on the ASX with its admission confirmed earlier this week. Its shares will be welcomed to Australia’s leading exchange today with trading expected […]